Prima awarded patent for CVac


The USPTO issues patent No. 8,771,701 entitled "Compositions for immunotherapy and uses thereof" protecting Prima BioMed's (PBMD +9.8%) CVac technology. CVac is a personalized immunotherapy. The patent's term extends to August 2022.

The patent covers the method of composition and the method of use of CVac, which uses the patient's own dendritic cells that are reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen. 

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs